We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Cooper Companies (COO) Receives ISO 15189 Accreditation
Read MoreHide Full Article
The Cooper Companies Inc. (COO - Free Report) announced that its London and Nottingham-based laboratories received the International Organization for Standardization (ISO) 15189 accreditation.
A glimpse of the company’s price trend reveals that the stock has had a strong run on the bourse year to date. Cooper Companies added 10.92% versus the Zacks classified Medical/Dental-Supplies sub-industry’s gain of 7.24%.
Despite the bullish price trend, estimate revision for the stock has been unfavourable. The ongoing quarter saw seven analysts move south over the last seven days and two moving in the opposite direction. As a result, the Zacks Consensus Estimate for the ongoing quarter fell by two cents to $2.25 over the same time frame. Presently, the stock has a Zacks Rank #3 (Hold). Coming back to the news, the accreditation was issued by the United Kingdom Accreditation Services (UKAS). The certification validates the quality and accuracy of the genetic testing services provided by the laboratories. The accreditation consists of noninvasive prenatal testing (NIPT), preimplantation genetic diagnosis (PGD), and preimplantation genetic screening (PGS) services provided in the London and Nottingham facilities. It is the first laboratory in the United Kingdom to receive such accreditation for NIPT and PGS services.
Going forward, the company is expected to maintain growth through leading positions in markets of speciality lenses with highly exclusive products like Bioinfinity, Clarity and silicone hydrogel lenses. The company's growing presence in the women's healthcare market through accretive acquisitions is also a positive in our view. Of the major concerns, an unfavorable foreign exchange rate, intensifying competition and volatility at distributor base might dent growth.
The Cooper Companies based in Pleasanton, CA, is a specialty medical device company operating on a global basis. Cooper operates through two business segments, namely CooperVision and CooperSurgical.
IDEXX Laboratories has a long-term expected earnings growth rate of approximately 15.04%. Notably, the stock has an impressive one-year return of 90.6%.
Avinger projects sales growth of 30.7% for the current year. In addition, the company posted a positive earnings surprise of 27% last quarter.
Fluidigm has a long-term expected earnings growth rate of 25%. Additionally, the company posted a positive earnings surprise of 1.6% last quarter.
8 Stocks with Huge Profit Potential
Just released: Driverless Cars: Your Roadmap to Mega-Profits Today. In this latest Special Report, Zacks’ Aggressive Growth Strategist Brian Bolan explores a full-blown technological breakthrough in the making – autonomous cars. He also spotlights 8 stocks with tremendous gain potential to feed off this phenomenon. Click to see the stocks right now >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Cooper Companies (COO) Receives ISO 15189 Accreditation
The Cooper Companies Inc. (COO - Free Report) announced that its London and Nottingham-based laboratories received the International Organization for Standardization (ISO) 15189 accreditation.
.jpg)
A glimpse of the company’s price trend reveals that the stock has had a strong run on the bourse year to date. Cooper Companies added 10.92% versus the Zacks classified Medical/Dental-Supplies sub-industry’s gain of 7.24%.
Despite the bullish price trend, estimate revision for the stock has been unfavourable. The ongoing quarter saw seven analysts move south over the last seven days and two moving in the opposite direction. As a result, the Zacks Consensus Estimate for the ongoing quarter fell by two cents to $2.25 over the same time frame. Presently, the stock has a Zacks Rank #3 (Hold).
Coming back to the news, the accreditation was issued by the United Kingdom Accreditation Services (UKAS). The certification validates the quality and accuracy of the genetic testing services provided by the laboratories. The accreditation consists of noninvasive prenatal testing (NIPT), preimplantation genetic diagnosis (PGD), and preimplantation genetic screening (PGS) services provided in the London and Nottingham facilities. It is the first laboratory in the United Kingdom to receive such accreditation for NIPT and PGS services.
Going forward, the company is expected to maintain growth through leading positions in markets of speciality lenses with highly exclusive products like Bioinfinity, Clarity and silicone hydrogel lenses. The company's growing presence in the women's healthcare market through accretive acquisitions is also a positive in our view. Of the major concerns, an unfavorable foreign exchange rate, intensifying competition and volatility at distributor base might dent growth.
The Cooper Companies based in Pleasanton, CA, is a specialty medical device company operating on a global basis. Cooper operates through two business segments, namely CooperVision and CooperSurgical.
Stocks to Consider
Better-ranked stocks in the broader medical sector include IDEXX Laboratories, Inc. (IDXX - Free Report) , Avinger, Inc. (AVGR - Free Report) and Fluidigm Corp. . All the three stocks carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 (Strong Buy) Rank stocks here.
IDEXX Laboratories has a long-term expected earnings growth rate of approximately 15.04%. Notably, the stock has an impressive one-year return of 90.6%.
Avinger projects sales growth of 30.7% for the current year. In addition, the company posted a positive earnings surprise of 27% last quarter.
Fluidigm has a long-term expected earnings growth rate of 25%. Additionally, the company posted a positive earnings surprise of 1.6% last quarter.
8 Stocks with Huge Profit Potential
Just released: Driverless Cars: Your Roadmap to Mega-Profits Today. In this latest Special Report, Zacks’ Aggressive Growth Strategist Brian Bolan explores a full-blown technological breakthrough in the making – autonomous cars. He also spotlights 8 stocks with tremendous gain potential to feed off this phenomenon. Click to see the stocks right now >>